• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

Alefacept response lingers in psoriatic patients

New Orleans - Psoriatic patients achieving >75 percentreduction in PASI score with one course of alefacept (Amevive) followedby treatment-free follow-up maintained >50 percent reduction for at leasteight months.

Related Videos
Related Content
Shanna Miranti, MPAS, PA-C, Shares Expert Acne and Pediatric Dermatology Insights
November 17th 2024

Shanna Miranti, MPAS, PA-C, Shares Expert Acne and Pediatric Dermatology Insights

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
August 1st 2023

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

Elimination Diets Have Little Impact on Pediatric Atopic Dermatitis, New Study Finds
October 24th 2024

Elimination Diets Have Little Impact on Pediatric Atopic Dermatitis, New Study Finds

The Cutaneous Connection
August 5th 2021

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

Psychosocial Impact of Alopecia Areata on Pediatric and Adolescent Patients
October 9th 2024

Psychosocial Impact of Alopecia Areata on Pediatric and Adolescent Patients

SPROUT Trial Highlights Benefits of Apremilast for Pediatric Psoriasis
September 12th 2024

SPROUT Trial Highlights Benefits of Apremilast for Pediatric Psoriasis

© 2024 MJH Life Sciences

All rights reserved.